MarketCap
Viridian Therapeutics VRDN
$ 30.86
2.25%
Facebook
X
Telegram
Viridian Therapeutics ROCE Ratio | VRDN
Annual ROCE Ratio Viridian Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.85 | -43.06 | -54.86 | -33.43 | -41.95 | -33.6 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -33.43 | -54.86 | -41.79 |
Quarterly ROCE Ratio Viridian Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -53.58 | -50.39 | -58.33 | -57.53 | -55.31 | -59.14 | -52.14 | -46.42 | -49.24 | -54.58 | -59.79 | -70.84 | -67.64 | -58.04 | -59.6 | -54.64 | -57.73 | -57.39 | -55.23 | -57.29 | -117.12 | -131.7 | -137.76 | -146.68 | -121.69 | -139.79 | -138.53 | -136.62 | -104.06 | -77.68 | -66.54 | -47.71 | -43.2 | -44.6 | -50.11 | -58.28 | -35.19 | -56.05 | -64.58 | -73.54 | -77.02 | -66.4 | -63.68 | -60.85 | -105.04 | -107.53 | -117.99 | -100.92 | -63.01 | -33.21 | -2.79 | - | - | 0.25 | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.25 | -146.68 | -71.62 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Dynavax Technologies Corporation
DVAX
|
-0.69 | - | - | $ 2.02 B |  USA |
 |
Intellia Therapeutics
NTLA
|
-59.74 | $ 11.18 | -7.72 % | $ 1.21 B | USA |
 |
Novartis AG
NVS
|
21.09 | $ 163.39 | -0.18 % | $ 317 B |  Schweiz |
 |
Omeros Corporation
OMER
|
101.29 | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Oramed Pharmaceuticals
ORMP
|
-7.12 | $ 3.97 | -0.75 % | $ 164 M |  Israel |
 |
Tyme Technologies
TYME
|
-31.86 | - | 8.07 % | $ 54 M | USA |
 |
Puma Biotechnology
PBYI
|
27.62 | $ 8.13 | -3.22 % | $ 407 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-340.95 | $ 1.02 | -5.09 % | $ 47.3 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-47.25 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Pfizer
PFE
|
10.69 | $ 29.34 | 0.36 % | $ 167 B | USA |
 |
Завод ДИОД
DIOD
|
5.84 | - | - | - |  Russia |
 |
PainReform Ltd.
PRFX
|
-58.14 | $ 0.78 | -4.24 % | $ 505 K | Israel |
 |
Prothena Corporation plc
PRTA
|
-75.06 | $ 8.56 | -2.51 % | $ 461 M | USA |
 |
Arcus Biosciences
RCUS
|
-61.17 | $ 18.66 | -1.56 % | $ 2 B | USA |
 |
Orgenesis
ORGS
|
155.73 | - | -33.86 % | $ 61.2 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
19.81 | $ 14.9 | -1.03 % | $ 12.4 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
11.45 | $ 916.16 | -0.41 % | $ 95.8 B | USA |
 |
Replimune Group
REPL
|
-116.69 | $ 23.3 | 4.67 % | $ 2.16 B | USA |
 |
Фармсинтез
LIFE
|
-4.03 | - | - | - | Russia |
 |
Royalty Pharma plc
RPRX
|
8.21 | $ 69.47 | 1.02 % | $ 29.9 B | USA |
 |
Revolution Medicines
RVMD
|
-57.28 | $ 193.0 | -3.57 % | $ 36.7 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-78.92 | $ 113.99 | 0.04 % | $ 7.41 B | USA |
 |
Codiak BioSciences
CDAK
|
-129.99 | - | -55.98 % | $ 2.15 M | USA |
 |
Sana Biotechnology
SANA
|
-74.02 | $ 2.43 | -1.42 % | $ 615 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-31.74 | $ 61.81 | 0.11 % | $ 172 M | Israel |
 |
Summit Therapeutics
SMMT
|
-57.38 | $ 17.78 | -0.34 % | $ 13.3 B |  Britain |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-66.67 | $ 9.43 | -0.89 % | $ 817 M | USA |
 |
Spero Therapeutics
SPRO
|
10.7 | $ 1.01 | -5.61 % | $ 56.6 M | USA |
 |
Sarepta Therapeutics
SRPT
|
-31.04 | $ 16.4 | -5.54 % | $ 1.64 B | USA |
 |
Tarsus Pharmaceuticals
TARS
|
-16.64 | $ 73.9 | 4.32 % | $ 3.09 B | USA |
 |
Bio-Techne Corporation
TECH
|
11.95 | $ 72.83 | -0.01 % | $ 11.4 B | USA |
 |
Sage Therapeutics
SAGE
|
-92.97 | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.01 | - | - | $ 1.62 B | Israel |
 |
Cabaletta Bio
CABA
|
-149.87 | $ 1.43 | -5.0 % | $ 144 M | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-34.91 | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-60.1 | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
7.56 | - | - | $ 26.6 B |  Irlanda |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-51.03 | $ 4.12 | -8.35 % | $ 35.1 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
27.02 | - | - | $ 121 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-83.7 | $ 11.55 | 4.52 % | $ 1.61 B |  France |
 |
Gilead Sciences
GILD
|
44.14 | $ 170.68 | 0.8 % | $ 212 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-44.75 | $ 4.28 | -2.06 % | $ 1.37 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-379.93 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-480.0 | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-27.03 | - | - | $ 411 M | USA |
 |
Gossamer Bio
GOSS
|
-156.9 | $ 11.2 | 5.21 % | $ 2.56 B | USA |
 |
GeoVax Labs
GOVX
|
-565.71 | $ 0.11 | -22.17 % | $ 105 K | USA |
 |
United Therapeutics Corporation
UTHR
|
20.39 | $ 588.33 | 1.01 % | $ 26.1 B | USA |